..... all smoke and mirrors ... no point adding this $10 million from Novaquest into the "Estimated Cash Available" when it is conditional upon the pediatric approval - that may not happen for 3-6 months.... so therefore they basically have this quarter and January to find capital from somewhere - $53M - $14M (Dec Quarter) = circa $39M less $35M minimum reserves = $4M left in Jan 2024
"An additional US$10.0 million from the loan will be drawn on marketing approval of remestemcel-L for the treatment in pediatric patients with steroid-refractory acute graft versus host disease"
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
"
(20min delay)